Advertisements

Sulinda

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Sulinda

Property Description
Active ingredient Sulindac
Form Oral tablet or capsule
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Anti-inflammatory and analgesic (pain-relieving)
Origin Synthetic organic compound

What is Sulinda and Its Active Ingredient?

Sulinda is a prescription medication containing the active ingredient Sulindac, which is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is prepared as a single-ingredient medication, typically formulated as an oral tablet or capsule. Chemically, Sulindac is characterized as an indene derivative and is listed within the acetic acid derivatives, placing it in a specific category of NSAIDs. This classification describes the drug's role in modulating processes associated with inflammation and discomfort.


Sulinda's Pharmacological Classification and Origin

Sulinda belongs to the NSAID pharmacological class, indicating its core function is to reduce the body's inflammatory response. The active substance, Sulindac, is a synthetic organic compound, produced entirely through controlled chemical synthesis. A key differentiating property of Sulindac is its status as a prodrug, meaning the compound is initially inactive. It requires metabolic activation within the liver, where it converts into the potent sulfide metabolite before achieving therapeutic efficacy. This metabolic process is necessary for the drug to achieve its therapeutic effect.


What is the General Purpose of Sulinda?

The general purpose of Sulinda is to provide anti-inflammatory and analgesic (pain-relieving) effects. It accomplishes this by reversibly inhibiting the prostaglandin synthetase enzyme system, thereby reducing the production of pro-inflammatory chemicals. This action helps manage symptoms such as swelling, stiffness, and associated discomfort by controlling the chemical cascade that drives inflammation.

Advertisements

What side effects are possible with Sulinda?

Possible side effects and safety information

The official safety profile of Sulindac (Sulinda) is organized by regulatory authorities to classify adverse reactions based on their frequency and the system-organ class affected, strictly reflecting documented risk.

Common and Expected Adverse Reactions

Adverse effects listed as common in regulatory documents typically involve the Gastrointestinal System (e.g., stomach pain, heartburn, nausea, diarrhea, constipation) and the Nervous System (headache, dizziness, nervousness). Other common reactions include edema (swelling) and tinnitus (ringing in the ears).

Serious Adverse Events

Regulatory labeling highlights specific serious adverse reactions. These include the documented risk of severe Gastrointestinal Adverse Events such as bleeding, ulceration, and perforation, which may be fatal and can occur without warning symptoms. There is also a documented risk of serious Cardiovascular Thrombotic Events, including myocardial infarction (heart attack) and stroke, which may occur early in treatment and generally increases with the duration of use.

Systemic and Population-Specific Safety Notes

Adverse reactions may affect the Hepatic System (liver, including rare reports of fatal failure) and the Renal System (kidneys, including renal impairment). Regulatory documents note specific population-specific safety considerations. Older adults are formally documented as being at a greater risk for serious gastrointestinal adverse events. Use is also formally constrained following Coronary Artery Bypass Graft (CABG) surgery and in individuals with a history of allergic-type reactions to aspirin or other NSAIDs.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose occurs when a person takes more than the recommended amount of Sulinda. Reported presentations following an overdose may include serious nervous system effects like stupor, coma, convulsions (seizures), agitation, and confusion. Other major manifestations can involve the cardiovascular and renal systems, such as hypotension (low blood pressure/shock) and diminished urine output or little to no urine production. Gastrointestinal symptoms, including nausea, vomiting (sometimes bloody), stomach pain, and diarrhea, are also commonly reported.

When to Get Emergency Medical Help

Immediate medical attention is required for an overdose or if you experience certain severe symptoms while taking this medication. These include:

  • Emergency Situations: If the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.
  • Signs of Serious Cardiovascular Events: Experiencing chest pain, shortness of breath, sudden weakness or numbness on one side of the body, or slurred speech.
  • Gastrointestinal Bleeding: Vomiting a substance that looks like coffee grounds or having black, tarry stools.

In the event of an overdose or life-threatening symptoms, immediately call emergency services (911). For urgent advice on poisoning, the national toll-free Poison Help hotline (1-800-222-1222) is available 24 hours a day in the United States.

Advertisements

Therapeutic Uses of Sulinda

What Sulinda Treats: Main Uses and Benefits

Sulinda is commonly used across conditions presenting with systemic or localized discomfort, and may be part of symptomatic management for chronic joint diseases such as Rheumatoid Arthritis, Osteoarthritis, and Ankylosing Spondylitis. It is also applied in clinical settings that involve acute or unstable symptom patterns, including conditions associated with acute or disruptive episodes of acute gouty arthritis, bursitis, and tendinitis.

It is relevant for managing symptom clusters that may become intense or disruptive, such as symptoms related to inflammatory or irritative states like joint swelling and stiffness. This provides support that contributes to easing the overall symptom load, particularly during phases when symptoms become more noticeable.

Beyond joint and soft tissue inflammation, Sulinda is considered relevant in conditions characterized by periods of heightened symptoms in a specific inherited disease: Familial Adenomatous Polyposis (FAP). This is a targeted application relevant in contexts involving symptoms linked to organ-specific functional stress, where it may be part of symptomatic management in this specific, non-analgesic context.

Quick Fact: Symptomatic Support Focus
Sulinda is commonly used to help with symptoms related to physical discomfort and symptoms that interfere with daily functioning across inflammatory conditions.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Sulinda?

This section outlines the official population eligibility criteria for Sulinda (Sulindac) as documented in regulatory labeling.


Populations for Whom Use is Contraindicated

Sulinda must not be used in the following populations:

  • Patients with known hypersensitivity to Sulindac or a history of asthma, urticaria, or allergic reactions after taking aspirin or other NSAIDs.
  • Individuals in the perioperative setting of Coronary Artery Bypass Graft (CABG) surgery.
  • Pregnant individuals from 20 weeks gestation and later.

Restricted and Conditional Use

Category Regulatory Status
Pediatric Patients Safety and effectiveness have not been established; use is generally not recommended.
Severe Renal Impairment Use should be avoided; close monitoring and dose reduction are required in all patients with impaired renal function.
Severe Hepatic Impairment Requires close monitoring; drug discontinuation is advised if toxicity occurs.
Older Adults Use is permitted but requires caution due to a greater risk of serious gastrointestinal and renal adverse events.
Severe Heart Failure Use should be avoided unless benefits outweigh the risk of worsening the condition.

Pregnancy and Lactation Eligibility

Use is contraindicated from 20 weeks of pregnancy onward. For lactating mothers, use is generally not recommended due to potential infant risk and lack of established safety data.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sulindac, the active component of Sulinda, has documented interactions with several drug classes and specific medicines, primarily affecting renal function and blood pressure regulation. These interactions are officially noted in regulatory documentation.

Documented Interaction Categories

Category/Substance Official Regulatory Constraint
Aspirin Co-administration is not recommended; it reduces the exposure to the active metabolite and increases adverse gastrointestinal events.
ACE-Inhibitors/ARBs May diminish the antihypertensive effect; increased risk of renal function deterioration, particularly in elderly or volume-depleted patients.
Diuretics (Furosemide/Thiazides) May reduce the natriuretic effect due to inhibited renal prostaglandin synthesis; requires monitoring of diuretic efficacy and renal function.
Lithium Reduces renal clearance, leading to elevated plasma lithium levels; patients must be carefully observed for signs of lithium toxicity.
Methotrexate May enhance toxicity due to competitive inhibition of its accumulation in the kidney; use with caution is advised.
Cyclosporine Associated with increased toxicity; requires careful monitoring of renal function when co-administered.
DMSO (Dimethyl Sulfoxide) Co-administration is not recommended; it reduces the plasma level of the active metabolite and has been linked to peripheral neuropathy.
Anticoagulants (e.g., Warfarin) Requires cautious use due to the potential for increased risk of bleeding.

Interaction Profile Summary

The official interaction profile is structured around the potential for sulindac to inhibit renal prostaglandin synthesis, which is the stated mechanistic basis for diminishing the effects of certain antihypertensives and diuretics, and for increasing the toxicity of other medicines such as lithium and methotrexate. Due to these risks, close patient monitoring and specific constraints, such as the recommendation against co-administering with aspirin or DMSO, are required to manage these official interaction concerns.

Advertisements

Mechanism of Action

Prodrug Activation and Target Inhibition

The mechanism of action begins with the inactive parent compound, Sulindac, which must undergo essential metabolic reduction—primarily in the liver—to become the active metabolite, Sulindac Sulfide. This active species then acts as a reversible, nonselective inhibitor of the Cyclooxygenase-1 ( COX-1) and Cyclooxygenase-2 ( COX-2) enzymes. This mandatory activation step dictates the rate of pathway engagement.


Modulation of the Eicosanoid Cascade

By inhibiting the COX enzymes, the active metabolite interrupts the conversion of arachidonic acid into prostaglandins ( PGE2, etc.). This suppression of prostaglandin synthesis modulates signaling activity within the inflammatory cascade. The resulting physiological effect is a change in the peripheral nociceptive threshold and local vascular tone, alongside decreased concentration of chemical signals promoting local vasodilation and nerve sensitization.


️ Mechanisms of Physiological Constraint

The efficacy of the pathway is constrained in situations where the metabolic activation (prodrug conversion) is impaired. Furthermore, the active Sulindac Sulfide is continuously oxidized back to inactive forms, meaning the mechanism's duration is intrinsically governed by the metabolic interconversion.

Advertisements

Dosage and Administration Information

How Sulinda is Used: General Administration

Sulinda, which contains the active ingredient sulindac, is an orally administered medication used according to structured protocols. The medicine is available as 150 mg and 200 mg tablets and is strictly for oral use.


Dosing and Frequency

Administration is typically structured as a twice-daily (bid) regimen. For chronic conditions like rheumatoid arthritis, the starting dose is usually 150 mg twice daily. For acute inflammatory episodes, such as acute gouty arthritis, the starting dose is often 200 mg twice daily. The maximum recommended daily dose is 400 mg. The overarching principle for use is to utilize the lowest effective dose for the shortest possible duration.


Administration Context and Duration

Tablets should be taken with food or an adequate amount of water to satisfy specific intake conditions. If a dose is missed, it is generally advised to take it as soon as possible, but if it is nearly time for the next scheduled dose, the missed dose should be skipped; doses must never be doubled. For acute conditions, such as bursitis or tendinitis, treatment typically lasts 7 to 14 days, while chronic use may require two weeks or more for the full therapeutic response to be realized.


Population-Specific Use

Specific considerations apply for use in certain populations. In patients with significant hepatic or renal impairment, a lower daily dose should be anticipated due to the drug's metabolism and excretion. The safety and efficacy of Sulinda in pediatric patients have not been established.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sulinda (Sulindac)

The research evidence for Sulinda (Sulindac) is derived from clinical trials and peer-reviewed studies that explore its use across specific inflammatory conditions and a specialized application for an inherited syndrome. This overview focuses strictly on the evidence landscape and the types of data summarized in authoritative sources, avoiding any clinical advice or interpretation of certainty.

Evidence for Chronic Joint Conditions: Osteoarthritis and Rheumatoid Arthritis

Research exploring Sulinda's use in chronic joint conditions, specifically Osteoarthritis (OA) and Rheumatoid Arthritis (RA), is documented primarily in randomized controlled trials (RCTs) and open-label studies involving adult populations. These trials were designed to observe changes over defined time intervals, often weeks to months, to see how symptoms were measured in the observed populations.

The outcomes monitored were related to physical discomfort and daily functioning, including the measurement of joint pain intensity, stiffness, and swelling. Findings describe patterns observed in the studies where measurements of change in these outcomes were recorded during the study periods. Long-term effects are not fully established regarding the full duration of these observed patterns, and evidence contributes to the broader evidence landscape.

Evidence for Acute Inflammation: Gouty Arthritis and Soft Tissue Disorders

Research examined Sulinda in conditions presenting with cycles of stability and flare-ups, such as acute gouty arthritis, Ankylosing Spondylitis, and local soft tissue inflammation like bursitis and tendinitis. Studies monitored outcomes linked to inflammatory or irritative states, including measurements of pain and the visible signs of acute inflammation.

Research in a Specialized Context: Familial Adenomatous Polyposis (FAP)

Sulinda was evaluated in research for Familial Adenomatous Polyposis (FAP), an inherited condition associated with the formation of numerous polyps. Studies for this application include randomized, double-blind, placebo-controlled trials specifically designed to assess changes in polyp formation. Researchers examined the total number and size of adenomatous polyps using endoscopic assessments over defined time intervals. Long-term effects on complex outcomes are not fully established, and research provides limited information for long-term outcomes or how treatment may influence the frequency of future episodic changes.

Research in Specific Patient Groups and Evidence Gaps

Research has explored the use of Sulinda in different age groups. Studies were performed in older adults, and these studies contribute to understanding symptom patterns in this population. Evidence is limited for the pediatric population, as appropriate studies was not evaluated in children. In chronic inflammation research, comparative evidence is lacking in large-scale studies directly assessing Sulinda against current prescription anti-inflammatory agents.

Key Studies & References

  1. Sulindac - StatPearls - NCBI Bookshelf (Clinical Indications and Population Summary)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Sulinda (FAQ)


Q: What is the main difference between Sulinda and similar medicines that treat the same condition?

A: Official information indicates that Sulinda is classified as a prodrug, meaning the compound is initially inactive and is converted into its active form by the liver. Its long-acting active metabolite is associated with its twice-daily dosing regimen.

Its unique mechanism is described in studies regarding its gastrointestinal side-effect profile.


Q: How quickly should someone start feeling the effects of Sulinda?

A: Official information indicates that the initial therapeutic response often begins within one week of starting treatment.

However, for more severe or chronic conditions, it may take two weeks or more for the full, maximum effects of the medicine to be realized.


Q: Can Sulinda be taken with common over-the-counter pain relievers?

A: Regulatory documents state that co-administration with Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) is generally not recommended.

This is because combining these medicines can increase the risk of serious gastrointestinal events. Regulatory information emphasizes the need to review all prescription and non-prescription medicines.


Q: Is it normal to feel tired or dizzy when first starting Sulinda?

A: Dizziness and headache are listed in official documents as common side effects associated with this medication.

However, unusual tiredness or unexplained weight gain are noted as potential warning signs of serious side effects, such as anemia or kidney issues. These symptoms warrant prompt attention from a healthcare provider.


Q: How long can a person safely stay on Sulinda?

A: The overarching regulatory principle for using this medicine is to utilize the lowest effective dose for the shortest possible duration of therapy.

The duration of treatment for chronic conditions is determined by the healthcare provider, but the risk of serious side effects, particularly cardiovascular events, generally increases with the length of use.


Q: Is it safe to drive or operate machinery while taking Sulinda?

A: Regulatory warnings indicate that Sulinda may cause dizziness, drowsiness, or blurred vision, which are Central Nervous System (CNS) effects that can potentially impair mental alertness.

Regulatory warnings state that caution is necessary when performing tasks that require mental alertness, such as driving or operating machinery.


Q: Is Sulinda safe for people with high blood pressure?

A: Official labeling states that Sulinda can lead to the onset of new hypertension or the worsening of existing high blood pressure.

Regulatory documents require that the medicine be used with caution in patients with pre-existing hypertension, and close monitoring of blood pressure is necessary throughout the course of therapy.


Q: What are the signs that Sulinda is actually working?

A: Official sources describe the medicine's purpose as relieving symptoms such as inflammation, swelling, stiffness, and joint pain.

Therefore, Sulinda is providing the intended effect when the patient experiences a reduction in these measurable symptoms related to their treated condition.


Q: Is it safe to take Sulinda before or after having minor surgery?

A: Sulinda is formally contraindicated (must not be used) in the perioperative setting of Coronary Artery Bypass Graft (CABG) surgery.

Because the medicine can prolong bleeding time, regulatory labels specify that precautions must be taken regarding its use around any surgical procedure.


Q: What is the typical time frame for clinical trials involving Sulinda?

A: Clinical study outcomes and efficacy are assessed over periods ranging from several weeks for acute symptoms.

Safety data, such as the incidence of serious gastrointestinal events, is often assessed over longer durations, including periods of three to six months and even one year.


Q: Does Sulinda cause weight gain or weight loss?

A: Unusual weight gain and swelling (edema) are listed in regulatory documents as potential warning signs of serious side effects, such as kidney damage.

These symptoms warrant prompt attention from a healthcare provider.


Q: Is Sulinda an opioid or habit-forming drug?

A: No. Sulinda contains the active ingredient sulindac, which is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and a nonopioid pain reliever.

It is not listed as a controlled substance by regulatory authorities and is not considered habit-forming.


Q: Are there specific foods or drinks that should be avoided while taking Sulinda?

A: Regulatory documents state that consuming alcohol (ethanol) should be avoided because it is a factor that increases the risk of serious stomach bleeding when combined with Sulinda.

Additionally, regulatory labels require the medicine to be taken with food or milk to help decrease gastrointestinal upset.


Q: Can Sulinda affect sleep or cause insomnia?

A: Nervousness is listed in regulatory product information as a common side effect of Sulinda.

This and other Central Nervous System (CNS) effects noted in official documents may potentially interfere with sleep patterns.


Q: Is there a generic version of Sulinda available?

A: Yes, the active ingredient, sulindac, is widely available and prescribed as a generic drug.


Q: Does Sulinda interact with supplements like vitamins or herbal products?

A: Sulinda has the potential to interact with certain herbal products (such as agrimony and alfalfa) and supplements.

Regulatory information emphasizes the importance of discussing all vitamins, herbs, and supplements with a healthcare provider.


Q: Why do people sometimes say Sulinda makes them feel 'foggy'?

A: This colloquial experience is often associated with the potential Central Nervous System (CNS) side effects noted in official documents.

These effects include dizziness, drowsiness, and other neurologic effects that can sometimes impair cognitive function.


Q: Does Sulinda need to be taken at the exact same time every day?

A: Sulinda is typically administered twice daily (bid) to maintain steady levels in the body.

Regulatory guidance regarding a missed dose states that it should be skipped if it is near the next scheduled dose.


Q: What should be done if an allergic reaction is suspected after taking Sulinda?

A: If signs of a severe allergic reaction occur, such as a severe rash, swelling of the face or throat, or trouble breathing, immediate discontinuation of the medication is required.

Prompt medical attention must then be sought.


Q: Does Sulinda contain gluten or any common allergens?

A: Official labeling lists the inactive ingredients in the formulation, which typically include substances like cellulose, magnesium stearate, and starch.

Patients with known allergies to non-medicinal components should check the full labeling of the dispensed product.


Q: Can Sulinda cause problems with vision or eyesight?

A: Yes, official safety documents list potential side effects affecting vision, including blurred vision and other changes in vision.

These symptoms warrant prompt attention from a healthcare provider.


Q: How long does Sulinda stay in the system after the last dose?

A: The clearance time of the drug from the body is determined by its half-life, which describes the time it takes for the concentration to decrease by half.

Regulatory data indicates the half-life is approximately 7.8 hours for the parent compound and 16.4 hours for the active metabolite.


Q: Are there any specific lifestyle changes recommended while on Sulinda?

A: Warnings exist regarding increased risk of serious side effects if consuming alcohol or smoking while taking the medication.

Caution is also required when performing tasks that demand mental alertness, such as driving or operating machinery.


Q: Why are there warnings about combining Sulinda with alcohol?

A: Alcohol (ethanol) is officially listed as a factor that significantly increases the risk of serious gastrointestinal adverse events.

This includes the potential for ulceration and bleeding in the stomach and intestines when combined with Sulinda.


Q: Do most patients tolerate Sulinda well?

A: Official clinical study data comparing Sulinda to aspirin indicated that Sulinda was generally well tolerated by patients.

The medicine was observed to be associated with an acceptable total incidence of adverse effects in the observed patient populations.


Q: If I stop taking Sulinda, will the symptoms immediately come back?

A: Sulinda provides symptomatic relief for conditions like arthritis and is not a cure for the underlying condition.

Its beneficial anti-inflammatory and pain-relieving effects are contingent on continued use.

Advertisements

How should Sulinda be stored and disposed of?

Sulinda (Sulindac) should be stored in its original container, tightly closed, at room temperature (between 68 F and 77 F or 20 C and 25 C). It is crucial to protect the medication from excessive heat, moisture, and direct light. Avoid storing it in the bathroom or near a sink.

Always keep Sulinda out of the reach of children and pets.

When disposing of this medication, do not flush tablets down the toilet or pour them down a drain unless specifically instructed to do so by a healthcare professional or an official medicine disposal program. The preferred method for disposing of unused or expired Sulinda is through a medicine take-back program or a community pharmacy that offers safe drug disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sulinda found in:

A-Z Index: